Go Pro
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel
NASDAQ:DBVT

DBV Technologies Q3 2026 Earnings Report

DBV Technologies logo
$10.55 -0.66 (-5.89%)
Closing price 04:00 PM Eastern
Extended Trading
$10.54 -0.01 (-0.05%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

DBV Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.66 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q3 2026
Date
10/28/2026
Time
Before Market Opens
Conference Call Date
Wednesday, October 28, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

DBV Technologies Earnings Headlines

DBV Technologies ADR (DBVT)
September 30 at 6:05 PM  |  za.investing.comhttps://za.investing.com/equities/dbv-technologies-consensus-estimates
DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children
September 30 at 6:05 PM  |  rttnews.comhttps://www.rttnews.com/3695038/dbv-seeks-fda-approval-for-viaskin-peanut-patch-in-young-children.aspx
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 2 at 1:00 AM  |  Stansberry Research (Ad)
DBV Technologies Submits US FDA Application for Potential Pediatric Peanut Allergy Patch
September 30 at 6:05 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dbv-technologies-submits-us-fda-101813800.html
DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy
September 29 at 12:53 AM  |  rttnews.comhttps://www.rttnews.com/3694992/dbv-submits-bla-for-viaskin-peanut-patch-in-children-with-peanut-allergy.aspx
DBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years
September 29 at 7:52 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69710265-dbv-technologies-s-a-dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-age-399.htm
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children. The company has also evaluated its epicutaneous immunotherapy platform in other allergy programs, including milk allergy. Viaskin Peanut has undergone clinical development and regulatory review in the United States, although it has not become an approved commercial treatment.

Founded in France, DBV Technologies operates internationally and has historically focused its development and regulatory activities on the United States and Europe. The company is headquartered in the Paris area and its American depositary shares trade on the Nasdaq under the symbol DBVT. Its leadership and corporate structure have changed over time as the company has advanced its clinical programs and worked with regulators.

View DBV Technologies Profile
Earnings Tools